Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.

ABSTRACT: Decitabine is a DNA-hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine is only around 30% and the overall survival remains poor. Emerging data support that regulation of DNA methylation is critical to control immune cell development, differentiation and activation. We hypothesize that defining how decitabine influences the immune responses in AML will facilitate the development of novel immune-based leukaemia therapeutics. Here, we performed phenotypic and functional immune analysis on clinical samples from AML patients receiving decitabine treatment and demonstrated a significant impact of decitabine on the immune system.

SUBMITTER: Zhao C 

PROVIDER: S-EPMC7065206 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature